TCL Archive NCI, Advisors Concur On Need For New Mechanism To Include Cancer Control, Minority Center Needs September 21, 1984
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
